



**T e c h n o l o g y
A s s e s s m e n t
P r o g r a m**

Office of Patient Care Services

UPDATED INFORMATION FOR VA TECHNOLOGY ASSESSMENT PROGRAM (VATAP) REPORTS

In June 2000, VATAP was relocated within the Veterans Health Administration from the Office of Research & Development to the Office of Patient Care Services. The following report was produced prior to the relocation of VATAP.

Current VATAP contact information is as follows:

VA Technology Assessment Program (11T)

VA Boston Healthcare System

150 South Huntington Avenue

Boston, MA 02130

Tel: 617.278.4469 Fax: 617.264.6587

vatap@med.va.gov

<http://www.va.gov/vatap> <http://vawww.va.gov/vatap>

TECHNOLOGY ASSESSMENT BRIEF

Stereotactic Radiosurgery for Treatment of Metastatic Brain Tumors Report #7

Contacts: Karen L. Flynn, DDS, MS, Elizabeth J. Adams, RRT, MPH, and
Elaine C. Alligood, MLS

Report Date: December 1997

Primary Objective: To assess the effectiveness of stereotactic radiosurgery (SRS) for the treatment of metastatic brain tumors.

Methods Used: Systematic review of published research.

Background: SRS is a specialized form of radiation therapy that delivers precisely focused beams of radiation to a targeted lesion in the brain. The intent is to destroy or control the lesion without harming healthy tissue. This technology has been used to treat a variety of brain abnormalities, and indications for its use are being expanded to include metastatic tumors to the brain.

Key Findings: The best available evidence from case studies suggests that SRS is a relatively safe and effective technology for treating brain metastases in selected patients; • SRS uses fewer resources than open cranial surgery; • patients with limited numbers of relatively small tumors and well-controlled systemic cancer appear to have gained the greatest benefits from SRS; • existing research does not permit valid comparisons of the relative effectiveness of SRS with other treatment options.

Conclusions/Recommendations:

- It is too early to draw definite conclusions about optimal treatment parameters.
- Additional research is needed to address the many unanswered questions concerning use of SRS for the treatment of brain metastases.